Earnings per share for the last twelve months: Veru Inc (VERU)
The success of Veru Inc. (VERU) relies on clinical trial results and capitalization for the development of obesity and cancer drugs. The rolling annual earnings per share demonstrates the resilience of the model, with the current mark equal to -0.61. Stable cash flow is ensured by patent protection for oncology drugs, although the decline in pandemic-related fees is forcing the company to reassess its competitive advantages.
Analytical breakdowns and data insights for company Veru Corporation (VERU)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation multiples indicators:
VERU - Net Financial Result|Expected Profit Veru Inc.|VERU - Price to Earnings Multiple|Forward P/E Multiple Veru Corporation|VERU - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Veru|VERU - Operating income before deduction of amortization|Net earnings per share for the last 12 months Veru|VERU - Earnings per share for the last twelve months|Quarterly EPS earnings growth verupharma.com|VERU - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Veru Inc.
- revenue and sales proceeds data:
General company analysis:verupharma.com - VERU
Net income per share over twelve months measures the portion of profit attributable to a single security after all expenses are deducted. For Veru Inc. (VERU), this metric reflects the efficiency of monetizing intellectual property within the oncology sector. By analyzing the fundamental TTM earnings per share, an investor can see the impact of FDA clinical trial costs. The metric's trend confirms the business's resilience, while steady growth indicates that regulatory barriers have been overcome.
Competitors of Veru Inc. (VERU)
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Biosciences, Inc.)|CADL: Net earnings per share (EPS TTM)|Accuray Inc (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group|Net earnings per share (EPS TTM) Actuate Therapeutics, Inc.|Earnings per share for the last twelve months citiusonc.com (CTOR)|Net earnings per share (EPS TTM) TuHURA (HURA)|Net earnings per share (EPS TTM) TARA (protaratx.com)|Earnings per share for the trailing year FATE|WHWK - Earnings per share for the last twelve months|Earnings per share for the trailing year TCRX (tscan.com)|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year TPST|XLO: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Renovaro RENB|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Kairos Pharma Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months OKUR|Net earnings per one share for the last twelve months CytoMed Therapeutics Limited GDTC|Net earnings per share (EPS TTM) CRIS|Net earnings per share (EPS TTM) Apollomics Inc. (APLM)|Net earnings per share (EPS TTM) THAR (Tharimmune Corp)|Net earnings per share for the last four quarters Advanced Biomed Inc (ADVB)|Genprex Inc - Net earnings per share (EPS TTM)|CLDI - Net earnings per share (EPS TTM)|Sunshine Biopharma Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
